Parkinson's disease (PD) is characterized by both motor and nonmotor deficits. Among
cardinal symptoms of this disorder, tremor is the least responsive to dopamine replacement …

Introduction and objective: Tremor is a disabling symptom of PD that usually responds
poorly to available standard pharmacological agents. This study aimed to assess the effect …

Major depressive disorder (MDD) is a common mental disorder with a high rate of morbidity
and mortality. Dysfunctional signaling of gamma-aminobutyric acid (GABA) has been …

Background: Gocovri®(amantadine) extended release capsules are approved for the
treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa-based …

Background: Clinical trials for antiparkinsonian drugs aimed at managing motor
complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into …

Background Dyskinesias are some of the major motor complications that impair quality of life
for patients with Parkinson's disease. The purpose of the present study was to investigate …

Objective: The pharmacological therapy for essential tremor (ET) is inadequate, and many
patients resort to surgical procedures. Zonisamide is an antiepileptic with several potential …

Abstract Background Zuranolone (SAGE-217) is a novel, investigational positive allosteric
modulator of GABA A receptors being investigated in major depressive disorder (MDD). This …

Tremor is a common symptom of Parkinson's disease (PD). The underlying pathophysiology
of parkinsonian rest tremor is not well understood. Rest tremor is less responsive to …

Dyskinesia is a significant clinical problem in patients with PD treated with dopaminergic
drugs. 1 Currently only amantadine meets evidence-based medical review criteria as …